Durvalumab (Imfinzi®). HTA ID: 23009

Assessment Status Full HTA submission received from Applicant
HTA ID 23009
Drug Durvalumab
Brand Imfinzi®
Indication Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer.
Assessment Process
Rapid review commissioned 20/02/2023
Rapid review completed 16/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab used in combination with gemcitabine and cisplatin compared with the current SOC (gemcitabine and cisplatin).
Full pharmacoeconomic assessment commissioned by HSE 29/03/2023
Pre-submission consultation with Applicant 06/06/2023
Full submission received from Applicant 04/10/2023